Presentation AmbrisanTM 5 Tablet: Each tablet contains Ambrisentan INN 5 mg. Pharmacology Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the e ects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. Ambrisentan is a high a nity ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known. Pharmacokinetics The pharmacokinetics of Ambrisentan (S-Ambrisentan) in healthy subjects are dose proportional. The absolute bioavailability of Ambrisentan is not known. Ambrisentan is absorbed with peak concentrations occurring approximately 2 hours after oral administration in healthy subjects and PAH patients. Food does not a ect its bioavailability. In vitro studies indicate that Ambrisentan is a substrate of P-gp. Ambrisentan is highly bound to plasma proteins (99%). The elimination of Ambrisentan is predominantly by non-renal pathways, but the relative contributions of metabolism and biliary elimination have not been well characterized. In plasma, the AUC of 4-hydroxymethyl Ambrisentan accounts for approximately 4% relative to parent Ambrisentan AUC. The in vivo inversion of S-Ambrisentan to R-Ambrisentan is negligible. The mean oral clearance of Ambrisentan is 38 mL/min and 19 mL/min in healthy subjects and in PAH patients, respectively. Although Ambrisentan has a 15-hour terminal half-life, the mean trough concentration of Ambrisentan at steady-state is about 15% of the mean peak concentration and the accumulation factor is about 1.2 after long-term daily dosing, indicating that the e ective half-life of Ambrisentan is about 9 hours. Indication and uses Ambrisentan is indicated for the treatment of Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening. Dosage and administration Initial treatment is 5 mg once daily, and can be increased to 10 mg once daily if 5 mg is tolerated. Tablets may be administered with or without food. Contraindications Ambrisentan may cause fetal harm when administered to a pregnant woman. Ambrisentan is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Pregnancy must be excluded before the initiation of treatment with Ambrisentan and prevented during treatment and for one month after stopping treatment. Ambrisentan is contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF) including IPF patients with pulmonary hypertension (WHO Group 3). Adverse e ect Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Ambrisentan. Warnings and precautions Fluid Retention: Peripheral edema is a known class e ect of endothelin receptor antagonists, and is also a clinical consequence of PAH and worsening PAH. Pulmonary Veno-occlusive Disease: If patients develop acute pulmonary edema during initiation of therapy with vasodilating agents such as Ambrisentan, the possibility of pulmonary veno-occlusive disease should be considered, and if con rmed. Ambrisentan should be discontinued. Hematological Changes: Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Ambrisentan. Hepatic impairment: Ambrisentan is not recommended in patients with moderate or severe hepatic impairment. Drug interactions Multiple dose co-administration of Ambrisentan and Cyclosporine resulted in an approximately 2-fold increase in Ambrisentan exposure in healthy volunteers; therefore, limit the dose of Ambrisentan to 5 mg once daily when co-administered with Cyclosporine. Use in pregnancy and lactation Pregnancy Category X. It is not known whether Ambrisentan is excreted in human milk. Breastfeeding while receiving Ambrisentan is not recommended. Pediatric use Safety and e ectiveness of Ambrisentan in pediatric patients have not been established. Storage condition Store in a cool and dry place, below 300 C. Protect from light and moisture. How supplied AmbrisanTM 5 Tablet: Each box contains 20 tablets in blister pack.

Online Medicine Shop is an online based medicine shop.Online Medicine shop delivered all kind of local and foreign legal medicine in chittagong city. We provide 24 houres service. You can order your needed medicine whole day but we will delivered your medicine from 7.00pm to 10.00pm. We also provide emergency service. Price of the medicine will be same as your nearest medicine shop.

TERMS & CONDITIONS

¤ No illegal medicine will be provided.
¤ Minimum Order Quantity 200TK
¤ For Blister 1 Blister minimum
¤ For Syrup Or pot, 1 pot or Syrup Minimum.
¤ Delivery Charge 100 TK. (Per order) it will be varried For Emergency Delivery.

----হ্যালো চট্টগ্রাম ----

Online Medicine Shop এ আপনাদের স্বাগতম। আপনার নিত্য প্রয়োজনীয় যে কোন ঔষধ আপনার ঠিকানায় পৌছে দিতে আমরা আছি আপনার পাশে। আপনার প্রয়োজনীয় ঔষধটি ঘরে বসেই অর্ডার করুন, আমরা পৌঁছে দিব দ্রুততম সময়ে, ন্যায্য মূল্যে আপনার ঠিকানায়।

www.onlinemedicinesshop.blogspot.com

Bangladesh pharmaceutical association

View 1+ more

Square Pharmaceuticals

@onlinemedicineshop

Beximco Pharma

ACI Limited

BEXIMCO

Eskayef Pharmaceuticals Ltd.

Incepta Pharmaceuticals

The ACME Labo

Vitamin D Levels Linked to Parkinson's Symptoms

Higher vitamin D levels are associated with better thinking and mood in people with Parkinson's disease, a new study suggests. The finding may lead to new ways to delay or prevent the onset of thinking problems and depression in people with the progressive neurodegenerative disease, the researchers said. Their analysis of nearly 300 Parkinson's disease patients revealed that higher blood levels of vitamin D -- the "sunshine vitamin" -- were associated with less severe physical symptoms, better thinking abilities and lower risk of depression. This link was especially strong in patients without dementia, according to the study in the current issue of the Journal of Parkinson's Disease. "About 30 percent of persons with [Parkinson's disease] suffer from cognitive impairment and dementia, and dementia is associated with nursing home placement and shortened life expectancy," study author Dr. Amie Peterson, of the Oregon Health and Sciences University, said in a journal news release. "We know mild cognitive impairment may predict the future development of dementia," she added. Preventing the development of dementia in these patients may potentially improve rates of illness and death related to Parkinson's disease, Peterson suggested. However, the study doesn't show whether low vitamin D dulls thinking or if the opposite is true -- that people with more advanced Parkinson's disease get less sun exposure because of their limited mobility and have lower levels of vitamin D as a result. The study also did not ask if patients were taking vitamin D supplements. While the study showed an association between vitamin D levels and thinking problems, it did not prove a cause-and-effect link. Vitamin D is absorbed by the body from sunlight. It is also found in foods such as fatty fish and in supplements. Low levels of vitamin D increase the risk of type 2 diabetes, multiple sclerosis, high blood pressure, cancer and infections, the study authors noted in the news release. Parkinson's disease affects about 1 million Americans and 5 million people worldwide. Its prevalence is expected to double by 2030. More information The U.S. National Institute of Neurological Disorders and Stroke has more about Parkinson's disease. Original Source: Journal of Parkinson's Disease, news release, Jan. 16, 2014 Artical source: Healthday.com

AIDS/HIV

AIDS has become a global epidemic and more than 47 million people have been infected with HIV since the first reports of the disease more than twenty years ago. This center provides basic information on the difference between HIV infection and AIDS, details the signs and symptoms of disease, lists means of preventing transmission of the virus and outlines the complications associated with AIDS/HIV as well as common drug treatments.

onlinemedicinesshop.blogspot.com

Medicine is the science and practice of establishing the diagnosis, prognosis, treatment, and prevention of disease. Medicine encompasses a variety of health care practices evolved to maintain and restore health by the prevention and treatment of illness.

onlinemedicinesshop.blogspot.com